ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Pharmaceuticals

Coronavirus trials for Actemra arthritis drug to start in Japan

Chugai and Roche's medication already set for tests in US

The trials will determine whether the arthritis treatment is effective against pneumonia caused by coronavirus infection.   © Reuters

TOKYO -- Chugai Pharmaceutical will conduct a clinical trial in Japan using its Actemra arthritis medication to treat patients with coronavirus-induced pneumonia.

The study's time frame and other details need to be finalized, the Tokyo-based company said Wednesday. Its Swiss parent, Roche Group, said last month that it was launching similar clinical trials in other countries including the U.S., where the Food and Drug Administration last month fast tracked the drug as a coronavirus treatment.

Actemra, released by Chugai in 2005, is approved to treat eight conditions including rheumatoid arthritis. The drugmaker hopes to add coronavirus-induced pneumonia to that list.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media